Peptide Purity Testing: HPLC, MS, Assay, and COAs

Peptide purity is not one number. A chromatographic area percentage, intact mass, assay result, biological activity result, sterility test, and bacterial endotoxin result answer different questions. A credible quality claim states which question was tested, which method was used, which specification applied, and which physical lot supplied the sample.

This guide explains how to read those claims. It does not certify a supplier, establish that a material is safe for human use, or replace product-specific quality, regulatory, or clinical review.

Purity is not one number

Start by separating the quality claim into attributes:

ICH Q6B notes that absolute purity is difficult to determine and that reported purity is method-dependent; it describes estimating purity with a combination of methods for biological products. The principle is useful when evaluating peptide data, but Q6B is not a declaration that every research peptide is a regulated biological product.

What HPLC and UPLC can show

Reversed-phase high-performance liquid chromatography (RP-HPLC), or the closely related UPLC format, is commonly used to separate a target peptide from related components. The sample passes through a column while the mobile-phase composition changes. Components interact differently with the stationary phase and may leave the column at different retention times. A detector records the resulting peaks.

An area-percent calculation is often presented as:

Assigned main-peak area / total integrated area × 100

That value is conditional on the entire method. It depends on sample preparation, column chemistry, mobile phase, gradient, temperature, flow, detector and wavelength, integration rules, reporting threshold, and treatment of solvent-front or unassigned peaks.

The main peak still needs an identity assignment

The largest chromatographic peak is not automatically the target peptide. A peak can be assigned through comparison with a suitable reference, peak collection and orthogonal characterization, or a coupled method such as LC-MS. Retention time alone is generally not a unique molecular identifier.

A defensible chromatographic result should make it possible to ask:

• Did the procedure separate the target from the most relevant known impurities?
• Could an impurity co-elute within the assigned main peak?
• Was system suitability met for this run?
• Was specificity demonstrated for the intended analytical purpose?
• Is the detector responsive to all components relevant to the claim?
• Were integration and reporting rules defined before the result was reviewed?
• Is the method stability-indicating when the result supports an expiration or storage claim?

ICH Q2(R2) describes validation characteristics such as specificity/selectivity, range, accuracy, precision, and detection or quantitation performance according to the procedure's intended purpose. ICH Q14 places that validation inside a broader, risk-based analytical-development process. A generic chromatogram without method identity, suitability, and a specification cannot demonstrate those controls.

Why area percent has limits

An HPLC detector measures response, not total vial composition. Relevant limitations include:

• Co-elution: two components can contribute to one apparent peak.
• Unequal response: different substances may not produce the same detector response per unit mass.
• Invisible material: water, many counterions, some solvents, and other components may not appear under the selected detection conditions.
• Excluded regions: solvent-front, blank, or reporting-threshold rules can change the denominator.
• Method dependence: a second column, gradient, detector, or separation principle can reveal components the first method did not resolve.

There is no universal HPLC percentage that makes a peptide suitable for cell, animal, or human use. Fitness depends on the exact material, experiment or product, impurity identities and risks, exposure, route, formulation, and all other relevant controls—not a generic “research grade” ladder.

What mass spectrometry can show

Mass spectrometry measures mass-to-charge ratios of ions. For peptides, electrospray ionization is frequently paired with liquid chromatography. Software may deconvolute multiple charge states to estimate an intact molecular mass. MALDI-TOF is another useful format in suitable contexts.

An intact mass compatible with the theoretical mass is evidence of compatibility, not unique proof of sequence. Molecules can share a nominal or exact mass; leucine and isoleucine are isobaric, stereochemical variants may be indistinguishable by ordinary intact-mass analysis, and different disulfide connectivities can require dedicated characterization. Adducts, in-source changes, unresolved mixtures, and co-elution also complicate interpretation.

Stronger identity or impurity evidence may combine:

1. chromatographic separation;
2. accurate intact mass;
3. fragmentation data from MS/MS;
4. peptide mapping or sequence coverage appropriate to the molecule;
5. characterization of terminal modifications, disulfide connectivity, conjugation sites, or stereochemistry when relevant; and
6. comparison with a qualified reference or an orthogonal spectroscopic method.

LC-MS is especially valuable for locating and characterizing peptide-related impurities. It is not automatically quantitative: different sequences and modified forms can have very different UV or ionization responses. A response factor, reference standard, calibration model, and validated range may be needed for an absolute amount claim.

HPLC purity, assay, and gross mass are different

HPLC area percent and assay are not interchangeable.

Water, counterions, salts, formulation components, and residual material can contribute to gross mass. Their relevance depends on the product and intended analytical question. Do not derive administration or dosing instructions from a seller's area-percent, fill-mass, or unspecified “peptide content” value.

Match each claim to a suitable method

No fixed panel fits every peptide. Sequence length, chemical modifications, conjugation, cyclic structure, aggregation risk, formulation, container, route, and intended use change what needs to be controlled.

Orthogonal does not merely mean “a second machine.” The most useful confirmation relies on a different measurement or separation principle and addresses a known weakness of the first method.

How to audit a certificate of analysis

A certificate of analysis (COA) is a report, not an independent guarantee. Its value depends on document authenticity, method suitability, sample provenance, and whether the result belongs to the lot in hand.

1. Match the exact product

Check the unambiguous peptide name or identifier, sequence, terminal groups, salt or counterion, isotopic or non-natural residues, conjugates, disulfide arrangement, and formulation. A certificate for a related sequence, free base, different salt, or unformulated active ingredient cannot be silently transferred to another presentation.

2. Match the physical lot

The report, container label, order record, and listing should carry the same batch or lot identifier. Record manufacturing, sampling, testing, release, retest, and expiration dates where applicable. A polished example certificate with no lot linkage is marketing material, not evidence for the received unit.

3. Map every claim to a result

For each claimed attribute, find the method identifier, specification, numerical result and units, and pass/fail decision. “Conforms” is difficult to interpret when the method and acceptance criteria are hidden. Theoretical mass is a calculation, not an observed result.

4. Inspect the method context

Look for method title and version, analytical mode, reference or standard, system-suitability status, reporting threshold, and any relevant sample preparation. Complete chromatograms, spectra, and integration tables can provide useful context, but screenshots alone do not prove authenticity or method validity.

5. Verify authorship and corrections

Identify the testing laboratory, authorized reviewer, report number, issue date, and version. If a result was corrected, the change should remain traceable rather than overwriting the original without explanation. A verification URL or direct confirmation channel can help establish that the lab issued the report.

6. Check sampling and chain of custody

Independent testing is only as representative as the sample. Ask who selected it, whether the laboratory received a sealed unit, how it was stored and shipped, and whether the sampled unit can be tied to inventory sold under the same lot. A seller-selected aliquot does not prove uniformity across every vial or shipment.

What “third-party tested” and accreditation mean

“Third-party tested” should identify the laboratory, report, sample, date, methods, and results. Independence reduces one conflict but does not repair poor sampling, an unsuitable method, undisclosed subcontracting, or a mismatched lot.

ISO/IEC 17025 is the current international standard used to assess testing and calibration laboratory competence. Accreditation is scope-specific. Verify the accreditation body's record and confirm that the relevant peptide test or method falls within the laboratory's accredited scope; a logo alone does not mean every service the lab offers is accredited. GLP, GMP, ISO certification, and ISO/IEC 17025 accreditation describe different systems and should not be used interchangeably.

Sterility and endotoxin are separate claims

An HPLC chromatogram and mass spectrum say nothing about sterility. Likewise, a sterility test is one part of a larger contamination-control and aseptic-manufacturing system; it cannot retroactively make an uncontrolled process sterile.

There is no universal endotoxin limit in EU/mg. FDA's March 2026 endotoxin guidance explains that limits and test conditions depend on the product, route, dose basis, compendial framework, and method suitability. The guidance also emphasizes sample handling and product-specific method verification. A result without its units, product basis, maximum valid dilution, interference controls, specification, and route context is incomplete.

“Research use only,” “injectable grade,” a sterile icon, or a bacterial-endotoxin result does not establish approval or suitability for administration. Use the administration evidence guide to separate route-specific evidence from seller presentation.

Red flags that deserve verification

Treat these as prompts to investigate, not automatic proof of misconduct:

• the report has no matching lot, report number, issue date, version, or laboratory identity;
• the same chromatogram, spectrum, result, or file appears under different lot numbers;
• only a cropped main peak is shown, with no integration table or method identity;
• the largest peak is labeled as target without orthogonal identity evidence;
• theoretical mass is presented as though it were an observed MS result;
• a purity percentage has no detector, method, reporting threshold, specification, or units;
• “third-party” is claimed without naming the lab or providing a verifiable report;
• HPLC or LC-MS is used to imply sterility, endotoxin control, potency, or total vial content;
• the certificate covers an active ingredient while the listing makes claims about a different finished presentation;
• an accreditation logo appears without an accessible certificate and relevant scope; or
• marketing language implies that a COA, test result, facility registration, or disclaimer is regulatory approval.

Price, packaging style, or a professional website is not analytical evidence in either direction.

A five-step lot review

Use this compact workflow when comparing a listing with its supporting evidence:

1. Identify: Write down the exact sequence, chemical form, presentation, claimed use category, and lot.
2. Map: Turn each marketing statement into an attribute—identity, related substances, assay, potency, physical quality, microbiological quality, or stability.
3. Match: Connect each attribute to a lot-specific method, specification, result, and unit.
4. Challenge: Ask what the method cannot detect and whether orthogonal evidence covers the important gap.
5. Trace: Verify the report issuer, version, sample provenance, chain of custody, and match to the received container.

Record unresolved fields as “not provided” rather than assuming they passed. For a repeatable scoring approach, use PepGuide's research methodology and source-evaluation framework. The source directory is a navigation and verification aid; inclusion is not a safety endorsement.

Put quality evidence in context

Quality testing answers what material may be in a lot. It does not establish that a peptide produces a desired human outcome. Evaluate those claims separately with the study-appraisal guide and the question-led use-case map.

For the upstream process, see How Peptides Are Made and Peptide Purification. For adjacent claim checks, use How to Evaluate “Premium Peptide” Claims, Peptide Storage and Reconstitution, and Peptide Solubility.

References

1. International Council for Harmonisation. Q6B: Specifications—Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. 1999.
2. International Council for Harmonisation. Q2(R2): Validation of Analytical Procedures. March 2024.
3. International Council for Harmonisation. Q14: Analytical Procedure Development. March 2024.
4. U.S. Food and Drug Administration. Pyrogen and Endotoxins Testing: Questions and Answers, Edition 2. March 2026.
5. U.S. Food and Drug Administration. Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. October 2004.
6. U.S. Food and Drug Administration. Revised draft product-specific guidances for generic peptide products. July 28, 2026. FDA states on this page that it withdrew the May 2021 general synthetic-peptide guidance because it no longer reflected the agency's current scientific thinking.
7. Van Dorpe S, et al. Characterization of synthetic peptide therapeutics using liquid chromatography–mass spectrometry: challenges, solutions, pitfalls, and future perspectives. Journal of Pharmaceutical and Biomedical Analysis. 2021.
8. Nanduri V, et al. Synthetic pharmaceutical peptides characterization by chromatography principles and method development. Journal of Separation Science. 2022.
9. Kilpatrick EL, et al. Assessing MS-based quantitation strategies for low-level impurities in peptide reference materials. Analytical and Bioanalytical Chemistry. 2018.
10. International Organization for Standardization. ISO/IEC 17025:2017—General requirements for the competence of testing and calibration laboratories. Confirmed current in 2023.